Montgomery Street

Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Mental Health, Other Health, Health, Pharmaceutical, Security (finance), Montgomery Street, Madison Avenue, Telephone, Jefferies, Exercise, William Blair & Company, Attention, Prospectus, Lexington Avenue, Jefferies Group, Neuroscience, Alto, Sale, Suite

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,206,000 additional shares, at a public offering price of $16.00 per share.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,206,000 additional shares, at a public offering price of $16.00 per share.
  • The aggregate gross proceeds to Alto from the offering were approximately $147.9 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto.
  • All of the shares of common stock were offered by Alto.
  • Alto’s common stock is listed on the New York Stock Exchange under the ticker symbol “ANRO.”
    Jefferies, TD Cowen, Stifel and William Blair acted as joint book-running managers for the offering.

Alto Neuroscience Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Friday, February 2, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Security (finance), Montgomery Street, Madison Avenue, Telephone, Jefferies, William Blair & Company, Attention, Prospectus, Lexington Avenue, Jefferies Group, Neuroscience, Alto, Sale, Suite

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share.
  • The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto.
  • In addition, Alto has granted the underwriters a 30-day option to purchase up to an additional 1,206,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • Jefferies, TD Cowen, Stifel and William Blair are acting as joint book-running managers for the offering.

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Janus, Citadel, Myopathy, Patient, Therapy, Research, SVB Securities, OrbiMed, Edgewise, Prospectus, Novo Holdings A/S, Form, Sale, Becker muscular dystrophy, ATTN:, Montgomery Street, Attention, Telephone, State Street

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.

Key Points: 
  • Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
  • Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses.
  • The closing of the offering is expected to occur on January 23, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Thursday, January 11, 2024
Jefferies, Therapy, Madison Avenue, Jefferies Group, 2nd Floor, DYN, Prospectus, Morgan Stanley, Form, Sale, Suite, Montgomery Street, J. P. Morgan, Attention, Telephone, Exercise, Varick Street, Security (finance), File, Oppenheimer Holdings, Broadridge Financial Solutions

The gross proceeds to Dyne from the offering were approximately $345.1 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne.

Key Points: 
  • The gross proceeds to Dyne from the offering were approximately $345.1 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne.
  • All of the shares in the offering were sold by Dyne.
  • Morgan Stanley, J.P. Morgan, Jefferies and Stifel acted as joint book-running managers for the offering.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statements.

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

Retrieved on: 
Friday, January 5, 2024
Telephone, Suite, 2nd Floor, Montgomery Street, Sale, Jefferies Group, Oppenheimer Holdings, Form, File, Attention, Jefferies, Therapy, J. P. Morgan, DYN, Varick Street, Prospectus, Madison Avenue, Broadridge Financial Solutions, Security (finance), Morgan Stanley

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share.

Key Points: 
  • WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share.
  • The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be approximately $300.1 million.
  • All shares in the offering are being sold by Dyne.
  • In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,572,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, January 3, 2024
Telephone, Suite, 2nd Floor, Montgomery Street, Sale, Jefferies Group, Oppenheimer Holdings, Form, Attention, Jefferies, Therapy, Dyne, J. P. Morgan, DYN, Varick Street, Prospectus, Madison Avenue, Broadridge Financial Solutions, Security (finance), Morgan Stanley

WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock.

Key Points: 
  • WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock.
  • Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock.
  • All of the shares in the proposed offering are to be sold by Dyne.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Eos Energy Announces Pricing of $50 Million Public Offering

Retrieved on: 
Friday, December 15, 2023
Telephone, Suite, Montgomery Street, Lexington Avenue, Sale, Eos, Form, Attention, Public expenditure, Form S-3, Prospectus, Security (finance)

The combined offering price to the public of each share of common stock and accompanying one common warrant is $1.45.

Key Points: 
  • The combined offering price to the public of each share of common stock and accompanying one common warrant is $1.45.
  • Before deducting the underwriting discounts and commissions and other offering expenses, Eos expects to receive total gross proceeds of approximately $50 million.
  • Eos intends to use the net proceeds from the offering for general corporate purposes, including working capital and capital expenditures.
  • The offering is being made only by means of a prospectus, consisting of a prospectus supplement and an accompanying prospectus.

Eos Energy Announces Launch of Proposed $40M Public Offering

Retrieved on: 
Thursday, December 14, 2023
Telephone, Suite, Montgomery Street, Lexington Avenue, Sale, Eos, Form, Attention, Form S-3, Prospectus, Security (finance)

All of the shares of common stock and accompanying common warrants are being offered by Eos.

Key Points: 
  • All of the shares of common stock and accompanying common warrants are being offered by Eos.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • TD Cowen and Stifel are acting as joint bookrunning managers in the proposed offering.
  • A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the proposed offering will be filed with the SEC.

Cibus Announces $20.3 Million Registered Direct Offering

Retrieved on: 
Tuesday, December 12, 2023
Telephone, Suite, Montgomery Street, Canaccord Genuity, Transition, Sale, CBUS, Research, Form, Rapeseed oil, Attention, SAN, Common stock, S-3, Common, Prospectus, Security (finance), Exercise, Offering

Cibus estimates the gross proceeds from this offering to be approximately $20.3 million before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of the Pre-Funded Warrants.

Key Points: 
  • Cibus estimates the gross proceeds from this offering to be approximately $20.3 million before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of the Pre-Funded Warrants.
  • The offering is expected to close on or about December 14, 2023, subject to the satisfaction of customary closing conditions.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.
  • The Offering may be made only by means of a prospectus supplement and accompanying prospectus.

HCI Group Announces Closing of Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, December 11, 2023
Telephone, Suite, Montgomery Street, Sale, Oppenheimer Holdings, Prospectus, HCI, Security (finance), ATTN:, Citizens Property Insurance Corporation, Exercise

This includes the exercise in full by the underwriters of their option to purchase up to an additional 150,000 shares of common stock in the offering, resulting in additional net proceeds to the company of approximately $11.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to an additional 150,000 shares of common stock in the offering, resulting in additional net proceeds to the company of approximately $11.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Total net proceeds to the company were approximately $85 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • HCI Group intends to use the net proceeds from the offering, including the proceeds received in connection with the exercise of the underwriters’ option, for general corporate purposes, including the continued assumption of policies from Citizens Property Insurance Corporation.
  • JMP Securities, a Citizens Company, acted as lead book-running manager for the offering, and Truist Securities acted as joint book-running manager.